Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
InChiKey: QHKYPYXTTXKZST-UHFFFAOYSA-N
SB-505124 selectively and concentration-dependently inhibits ALK4-
Halofuginone for fibrosis
trade name Picato
GSK-LSD1 was used at 1 µM in vitro
Vemurafenib - CAS# 918504-65-1 0069 InChiKey: QHKYPYXTTXKZST-UHFFFAOYSA-NVemurafenib, CAS No. 918504 65 1, also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP competitive, small molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late stage melanoma on August 17, 2011. Vemurafenib selectively binds to the ATP binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over